Literature DB >> 17636035

Androgen receptor structural and functional elements: role and regulation in prostate cancer.

Scott M Dehm1, Donald J Tindall.   

Abstract

The androgen receptor (AR) is a nuclear receptor transcription factor that mediates the cellular actions of androgens, the male sex steroids. Androgen-dependent tissues, such as the prostate, rely on androgen action for their development as well as their maintenance in adulthood. This requirement is exploited during systemic therapy of prostate cancer, which is initially an androgen-dependent disease. Indeed, androgen ablation, which prevents the production or blocks the action of androgens, inhibits prostate cancer growth. Invariably, the disease recurs with a phenotype resistant to further hormonal manipulations. However, this so-called androgen depletion-independent prostate cancer remains dependent on a functional AR for growth. Many studies have focused on the mechanistic and structural basis of AR activation with the important goal of understanding how the AR is activated at this stage of the disease. In this review, we summarize how these studies have revealed important functional domains in the AR protein and have provided initial clues to their role in prostate cancer development and progression. A comprehensive understanding of the role and functional relationships between these AR domains could lead to the development of novel AR-directed therapies for prostate cancer.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17636035     DOI: 10.1210/me.2007-0223

Source DB:  PubMed          Journal:  Mol Endocrinol        ISSN: 0888-8809


  107 in total

1.  The oncogenic gene fusion TMPRSS2: ERG is not a diagnostic or prognostic marker for ovarian cancer.

Authors:  Lillian Huang; Isaiah G Schauer; Jing Zhang; Imelda Mercado-Uribe; Michael T Deavers; Jiaoti Huang; Jinsong Liu
Journal:  Int J Clin Exp Pathol       Date:  2011-09-15

2.  Piperlongumine induces rapid depletion of the androgen receptor in human prostate cancer cells.

Authors:  Konstantin V Golovine; Peter B Makhov; Ervin Teper; Alexander Kutikov; Daniel Canter; Robert G Uzzo; Vladimir M Kolenko
Journal:  Prostate       Date:  2012-05-16       Impact factor: 4.104

3.  Methoxychalcone inhibitors of androgen receptor translocation and function.

Authors:  Yeong Sang Kim; Vineet Kumar; Sunmin Lee; Aki Iwai; Len Neckers; Sanjay V Malhotra; Jane B Trepel
Journal:  Bioorg Med Chem Lett       Date:  2012-01-21       Impact factor: 2.823

4.  Androgen receptor splice variants activate androgen receptor target genes and support aberrant prostate cancer cell growth independent of canonical androgen receptor nuclear localization signal.

Authors:  Siu Chiu Chan; Yingming Li; Scott M Dehm
Journal:  J Biol Chem       Date:  2012-04-24       Impact factor: 5.157

Review 5.  Histone modifications and chromatin organization in prostate cancer.

Authors:  Zhong Chen; Liguo Wang; Qianben Wang; Wei Li
Journal:  Epigenomics       Date:  2010-08       Impact factor: 4.778

6.  Coregulator control of androgen receptor action by a novel nuclear receptor-binding motif.

Authors:  Katja Jehle; Laura Cato; Antje Neeb; Claudia Muhle-Goll; Nicole Jung; Emmanuel W Smith; Victor Buzon; Laia R Carbó; Eva Estébanez-Perpiñá; Katja Schmitz; Ljiljana Fruk; Burkhard Luy; Yu Chen; Marc B Cox; Stefan Bräse; Myles Brown; Andrew C B Cato
Journal:  J Biol Chem       Date:  2014-02-12       Impact factor: 5.157

7.  NBBS isolated from Pygeum africanum bark exhibits androgen antagonistic activity, inhibits AR nuclear translocation and prostate cancer cell growth.

Authors:  Maria Papaioannou; Sonja Schleich; Daniela Roell; Undine Schubert; Tamzin Tanner; Frank Claessens; Rudolf Matusch; Aria Baniahmad
Journal:  Invest New Drugs       Date:  2009-09-23       Impact factor: 3.850

Review 8.  Constitutive activity of the androgen receptor.

Authors:  Siu Chiu Chan; Scott M Dehm
Journal:  Adv Pharmacol       Date:  2014

9.  ERK and AKT signaling drive MED1 overexpression in prostate cancer in association with elevated proliferation and tumorigenicity.

Authors:  Feng Jin; Shazia Irshad; Wei Yu; Madesh Belakavadi; Marina Chekmareva; Michael M Ittmann; Cory Abate-Shen; Joseph D Fondell
Journal:  Mol Cancer Res       Date:  2013-03-28       Impact factor: 5.852

10.  Transcriptional activity of c-Jun is critical for the suppression of AR function.

Authors:  Chih-Chao Hsu; Chang-Deng Hu
Journal:  Mol Cell Endocrinol       Date:  2013-03-21       Impact factor: 4.102

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.